{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:18Z","timestamp":1791357378916,"version":"4.3.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"iX Biopharma Pty Ltd, Australia, manufacturer of sublingual buprenorphine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/pm\/pnx321","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T04:14:57Z","timestamp":1511842497000},"page":"143-152","source":"Crossref","is-referenced-by-count":13,"title":["The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine"],"prefix":"10.1093","volume":"20","author":[{"given":"Stephen Chin Beng","family":"Lim","sequence":"first","affiliation":[{"name":"iX Biopharma Pty Ltd, Willetton, Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schug","sequence":"additional","affiliation":[{"name":"Medical School"},{"name":"Royal Perth Hospital"},{"name":"UWA Anaesthesiology, Perth, Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janakan","family":"Krishnarajah","sequence":"additional","affiliation":[{"name":"iX Biopharma Pty Ltd, Willetton, Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"issue":"6","key":"key\n\t\t\t\t2019011111180272000_pnx321-B1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1399-6576.1980.tb01584.x","article-title":"Double-blind, multidose comparison of buprenorphine and morphine in postoperative pain","volume":"24","author":"Tigerstedt","year":"1980","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2\u20133","key":"key\n\t\t\t\t2019011111180272000_pnx321-B2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/j.1552-4604.1981.tb01761.x","article-title":"The study of analgesics following single and repeated doses","volume":"21","author":"Wang","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"key\n\t\t\t\t2019011111180272000_pnx321-B3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/j.1552-4604.1981.tb01774.x","article-title":"Multidose\/observational, comparative clinical analgesic evaluation of buprenorphine","volume":"21","author":"Mok","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"key\n\t\t\t\t2019011111180272000_pnx321-B4","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/00000542-200606000-00019","article-title":"Mechanism-based pharmacokinetic\u2013pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers","volume":"104","author":"Yassen","year":"2006","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3565(25)24425-1","article-title":"Comparative analysis of buprenorphine- and norbuprenorphine induced analgesic effects based on pharmacokinetic pharmacodynamic modelling","volume":"272","author":"Ohtani","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"key\n\t\t\t\t2019011111180272000_pnx321-B6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.sjpain.2013.05.004","article-title":"Buprenorphine-clinically useful but often misunderstood","volume":"4","author":"Butler","year":"2013","journal-title":"Scand J Pain"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0310057X1704500217","article-title":"Buprenorphine-related complications in elderly hospitalised patients: A case series","volume":"45","author":"Richards","year":"2017","journal-title":"Anaesth Intensive Care"},{"issue":"3","key":"key\n\t\t\t\t2019011111180272000_pnx321-B9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: Considerations for pain management","volume":"29","author":"Johnson","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"key\n\t\t\t\t2019011111180272000_pnx321-B10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","article-title":"Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine","volume":"13","author":"Kress","year":"2009","journal-title":"Eur J Pain"},{"issue":"6","key":"key\n\t\t\t\t2019011111180272000_pnx321-B11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"issue":"1\u20132","key":"key\n\t\t\t\t2019011111180272000_pnx321-B12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pain.2005.06.030","article-title":"Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model","volume":"118","author":"Koppert","year":"2005","journal-title":"Pain"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"key\n\t\t\t\t2019011111180272000_pnx321-B14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pain.2005.07.021","article-title":"Opioids: From analgesia to anti-hyperalgesia?","volume":"118","author":"Simonnet","year":"2005","journal-title":"Pain"},{"issue":"1","key":"key\n\t\t\t\t2019011111180272000_pnx321-B15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jc.2004-0929","article-title":"Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence","volume":"90","author":"Bliesener","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2605.2007.00824.x","article-title":"Hypogonadismin men receiving methadone and buprenorphine maintenance treatment","volume":"32","author":"Hallinan","year":"2009","journal-title":"Int J Androl"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1054\/jpai.2002.126790","article-title":"Hypogonadism in men consuming sustained-action oral opioids","volume":"3","author":"Daniell","year":"2002","journal-title":"J Pain"},{"issue":"22","key":"key\n\t\t\t\t2019011111180272000_pnx321-B18","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam","year":"2007","journal-title":"Arch Intern Med"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jpainsymman.2013.03.001","article-title":"Buprenorphine","volume":"45","author":"Foster","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinthera.2015.12.004","article-title":"Differentiating the effect of an opioid agonist on cardiac repolarization from micro-receptor mediated, indirect effects on the QT interval: A randomized, 3-way crossover study in healthy participants","volume":"38","author":"Darpo","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"issue":"10","key":"key\n\t\t\t\t2019011111180272000_pnx321-B22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s12325-012-0051-7","article-title":"Opioid rotation in clinical practice","volume":"29","author":"Nalamachu","year":"2012","journal-title":"Adv Ther"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B23","first-page":"899","article-title":"Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine","volume":"17","author":"Webster","year":"2017","journal-title":"Pain Med"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: A review of its pharmacological properties and therapeutic efficiency","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B25","year":"2016"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B26","year":"2005"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B27","first-page":"1","article-title":"In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation","volume":"7","author":"Lim","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B28","author":"World Medical Association (WMA) Declaration of Helsinki","year":"2000"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B29","author":"European Agency for the Evaluation of Medicinal Products (EMEA)"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/JPR.S87952","article-title":"Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology","volume":"9","author":"Pergolizzi","year":"2016","journal-title":"J Pain Res"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clinthera.2015.12.016","article-title":"Evaluation of the pharmacokinetics of single and multi-dose buprenorphine buccal film in healthy volunteers","volume":"38","author":"Bai","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"key\n\t\t\t\t2019011111180272000_pnx321-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.2600810102","article-title":"Drug delivery via the mucous membranes of the oral cavity","volume":"81","author":"Harris","year":"1992","journal-title":"J Pharm Sci"},{"issue":"11","key":"key\n\t\t\t\t2019011111180272000_pnx321-B33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.2042-7158.1989.tb06374.x","article-title":"The systemic availability of buprenorphine administered by nasal spray","volume":"41","author":"Eriksen","year":"1989","journal-title":"J Pharm Pharmacol"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B34","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2014.05.060","article-title":"Buccal and sublingual vaccine delivery","volume":"190","author":"Kraan","year":"2014","journal-title":"J Control Release"},{"issue":"1","key":"key\n\t\t\t\t2019011111180272000_pnx321-B35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019011111180272000_pnx321-B36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/03639045.2013.846365","article-title":"Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine\/naloxone tablet formulation in healthy volunteers","volume":"41","author":"Fischer","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"key\n\t\t\t\t2019011111180272000_pnx321-B37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0376-8716(03)00188-1","article-title":"Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block","volume":"72","author":"McAleer","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200443050-00005","article-title":"Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: Lack of dose proportionality","volume":"43","author":"Harris","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"key\n\t\t\t\t2019011111180272000_pnx321-B39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1982.tb01434.x","article-title":"Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis","volume":"13","author":"Bullingham","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"key\n\t\t\t\t2019011111180272000_pnx321-B40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"issue":"6","key":"key\n\t\t\t\t2019011111180272000_pnx321-B41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/ecp.11.59","article-title":"Pharmacokinetic-pharmacodynamic modelling in acute and chronic pain: An overview of the recent literature","volume":"4","author":"Martini","year":"2011","journal-title":"Expert Rev Clin Pharmaciol"},{"key":"key\n\t\t\t\t2019011111180272000_pnx321-B42","first-page":"789","article-title":"Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences","volume":"25","author":"Megarbane","year":"2006","journal-title":"Toxicol Rev"},{"issue":"2","key":"key\n\t\t\t\t2019011111180272000_pnx321-B43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/17425255.2014.864636","article-title":"Pharmacokinetic and pharmacodynamic modelling for acute and chronic pain drug assessment","volume":"10","author":"Yang","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/20\/1\/143\/27495516\/pnx321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T15:41:01Z","timestamp":1751038861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/20\/1\/143\/4788299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,3]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnx321","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,1,3]]}}}